Our new Cryptocurrency section has arrived! Click here

Less Ads, More Data, More Tools Register for FREE

Cathal Friel, CEO of pharma services company #OpenOrphan explains the investment opportunity

#ORPH. Cathal Friel, Open Orphan CEO explains how he plans to buy and build a pharma services company. He believes the pharma rare orphan asset space is the hot spot at the moment, and providing services to those pharmas hoping to commercialise drugs is the strategy.

Open Orphan have been building a pharma contacts platform for a couple of years and recently reversed Open Orphan into a business called Venn Life Sciences, giving them an AIM listing and pre-exisisting revenues of £14M.

#ORPH have just raised £4.5M from institutions and have been looking at acquisitions. The services sector is very fragmented and Orphan see a consolidation opportunity.

Pharma Services company Open Orphan presenting at Hardman's November Forum

Hardman Investor Forum: Primary Health Properties, Open Orphan, Surface Transforms, NSF

Cathal Friel, CEO, Open Orphan, #ORPH at the London South East Life Sciences Investor Briefing

Related Shares

Login to your account

Don't have an account? Click here to register.